Novocure

Novocure is an international oncology company founded in 2000 by Professor Yoram Palti, known for discovering the therapeutic effects of Tumor Treating Fields (TTFields) on cancer cells. Headquartered in Saint Helier, Jersey, UK, Novocure operates in the United States, Germany, Japan, Greater China, and other international markets. The company specializes in developing and commercializing delivery systems that utilize its proprietary TTFields technology. This non-invasive treatment approach targets solid tumor cancer cells by using low-intensity, intermediate-frequency electric fields to disrupt their division and inhibit tumor growth. Novocure's key products include Optune Lua, for malignant pleural mesothelioma, and Optune Gio, for glioblastoma. Both products are designed to be used alongside standard chemotherapy regimens to enhance treatment efficacy. Novocure is committed to expanding the applications of TTFields therapy through clinical research, having participated in over 80 medical trials worldwide.

• Employees1500
• Founded2000
• Annual Revenue$605220000
• Total Funding$1390000000